Combination Approaches Are on the Horizon in Later-Line HER2+ Breast Cancer Management
July 18th 2023Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management.
Read More
Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets
July 18th 2023Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.
Read More
HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents
July 17th 2023Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape.
Read More
Novel Radiotherapy Supports Precision Medicine Advances in Lung and Bone Cancers
July 13th 2023Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers, the benefits SCINTIX technology can provide for these patients, and how John Theurer Cancer Center plans to use this technology to improve patient outcomes and support further radiation therapy research.
Read More
Anemia-Focused Treatment Approaches Represent Future Directions in Myelofibrosis
July 12th 2023Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.
Read More
Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care
July 11th 2023Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.
Read More
PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma
July 10th 2023Varun Monga, MBBS, discusses the mechanism of action of PRT811, key efficacy and safety findings from a phase 1 trial investigating the agent, and potential future directions with this agent in uveal melanoma and IDH-mutant high-grade glioma.
Read More
CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer
July 8th 2023Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.
Read More
TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1
July 5th 2023Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.
Read More
Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer
June 30th 2023Bradley J. Monk, MD, FACS, FACOG, discusses the rationale for investigating avutometinib plus defactinib in patients with low-grade serous ovarian cancer, key findings from RAMP 201, and how this research may influence the ovarian cancer treatment paradigm going forward.
Read More
Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma
June 26th 2023Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.
Read More
AUTO4 CAR T-Cell Therapy Is Well Tolerated in R/R TRBC1+ Peripheral T-Cell Lymphoma
June 22nd 2023The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities and led to early indications of efficacy in patients with relapsed/refractory TRBC1-positive peripheral T-cell lymphoma.
Read More
Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm
June 22nd 2023Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs.
Read More
Study Protocol Differences May Affect BTK Inhibitor Performance in R/R CLL
June 21st 2023Patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib in the phase 3 RESONATE trial achieved a significantly longer median progression-free survival compared with those in the phase 3 ALPINE trial, as well as a higher yet nonsignificant 2-year PFS estimate vs those in the phase 3 ELEVATE-RR trial.
Read More
Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors
June 16th 2023Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.
Read More
Real-World Analysis Supports Use of Brexu-Cel in Relapsed/Refractory MCL
June 15th 2023The real-world efficacy and safety of brexucabtagene autoleucel were similar to the outcomes seen in the phase 2 ZUMA-2 trial, regardless of patients’ treatment history, according to results from a real-world subgroup analysis of patients with relapsed/refractory mantle cell lymphoma.
Read More
Frontline Pembrolizumab Plus Lenvatinib Has Antitumor Activity in Non–clear Cell RCC
June 14th 2023The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.
Read More
Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC
June 13th 2023The combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered as triplet therapy in patients with PD-L1–high, metastatic non–small cell lung cancer.
Read More
Phase 1 Data Support Further Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma
June 12th 2023The FGFR2 inhibitor RLY-4008 generated early evidence of efficacy in patients with cholangiocarcinoma harboring FGFR2 fusions, according to findings from the phase 1/2 ReFocus trial, which were presented at the 2023 ASCO Annual Meeting.
Read More
Panitumumab Plus Trifluridine-Tipiracil Improves Outcomes in RAS Wild-type mCRC
May 31st 2023The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.
Read More
PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment Options
May 31st 2023Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.
Read More
Shifts In Ovarian Cancer Treatment Options Necessitate Continued Research
May 29th 2023Whitfield B. Growdon, MD, discusses the role PARP inhibitors have played in ovarian cancer since their introduction to the field, the updated clinical trial data that contributed to the indication withdrawals for these agents, and where future research in this area may be headed.
Read More
Advances in Precision Medicine Propel Personalized GI Cancer Care
May 25th 2023Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.
Read More
METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL
May 24th 2023Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.
Read More
Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer
May 23rd 2023Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.
Read More
Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors
May 23rd 2023Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.
Read More